Azamgarhi, T;
Warren, S;
Fouch, S;
Standing, JF;
Gerrand, C;
(2023)
Prophylactic antibiotics for massive endoprostheses in orthopaedic oncology.
Bone and Joint Journal
, 105 E
(8)
pp. 850-856.
10.1302/0301-620X.105B8.BJJ-2022-1418.R1.
Preview |
Text
Standing_Antimicrobial_Prophylaxis_in_Orthopaedic_Oncology_review-_23-12-2022-FINAL-REVISION-31-03-2023.pdf Download (396kB) | Preview |
Abstract
The recently published Prophylactic Antibiotic Regimens In Tumor Surgery (PARITY) trial found no benefit in extending antibiotic prophylaxis from 24 hours to five days after endoprosthetic reconstruction for lower limb bone tumours. PARITY is the first randomized controlled trial in orthopaedic oncology and is a huge step forward in understanding antibiotic prophylaxis. However, significant gaps remain, including questions around antibiotic choice, particularly in the UK, where cephalosporins are avoided due to concerns of Clostridioides difficile infection. We present a review of the evidence for antibiotic choice, dosing, and timing, and a brief description of PARITY, its implication for practice, and the remaining gaps in our understanding.
Archive Staff Only
 |
View Item |
